ArticleFrontiers in neurology2025
Radiomics prediction of MGMT promoter methylation in adult diffuse gliomas: a combination of structural MRI, DCE, and DTI.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the predictive value of radiomics features extracted from structural MRI, dynamic contrast enhanced (DCE), and diffusion tensor imaging (DTI) in detecting O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in patients with diffuse gliomas. Methods: Retrospective MRI data of 110 patients were enrolled in this study. The training dataset included 88 patients (mean age 52.84 ± 14.71, 47 females). The test dataset included 22 patients (mean age 50.64 ± 12.58, 12 females). A total of 2,782 radiomic features were extracted from structural MRI, DCE, and DTI within two region of interests (ROIs). Feature section was conducted using Pearson correlation and least absolute shrinkage and selection operator. Principal component analysis was utilized for dimensionality reduction. Support vector machine was employed for model construction. Two radiologists with 1 year and 5 years of experience evaluated the MGMT status in the test dataset as a comparison with the models. The chi-square test and independent samples Results: On the training dataset, the model structural MRI + DCE achieved the highest AUC of 0.906. On the test dataset, the model structural MRI + DCE + DTI achieved the highest AUC of 0.868, outperforming two radiologists. Conclusion: The radiomics models have obtained promising performance in predicting MGMT promoter methylation status. Adding DCE and DTI features can provide extra information to structural MRI in detecting MGMT promoter methylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.